COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis

Protocol No
CAELUM-CAEL101-301
Principal Investigator
Anita D'Souza
Phase
III
Summary
This study will look at whether an investigational drug, CAEL-101, in combination with standard treatment, is better than standard treatment alone for AL amyloidosis Mayo Stage IIIb.
Description
A Study to Evaluate the Effectiveness & Safety of CAEL-101 in Patients w/ Mayo Stage IIIb AL Amyloid
Participating Institutions
Froedtert Hospital
Status
IRB INITIAL APPROVAL